Jump to:

Irene Orlow

Associate Attending Biologist

Office Phone

212-639-3072

Office Fax

212-717-3666

Email

orlowi@mskcc.org

Education

University of Buenos Aires

Current Research Interests/Research Goals

Dr. Orlow leads the Molecular Epidemiology Laboratory. Her research interests focus on the identification of host and tumor genetic and phenotypic characteristics affecting cancer risk and progression, with the ultimate goal of improving existing diagnostic tools, particularly in melanoma, lung, and bladder cancer. With the assistance of the laboratory staff, she also supports other investigators in assessment of cancer risk, prevention, surveillance, and clinical and cognitive outcomes in studies of glioma, sarcoma, pancreatic, endometrial, ovarian, and breast cancer.

As a member of the Melanoma Disease Management Team, she has built and maintains a ten-year collection of biospecimens from patients with melanoma as a resource for epidemiologic and longitudinal studies, and participates in efforts to assess risk for development and progression of the disease. Further work in melanoma with colleagues from the international Genes, Environment, and Melanoma Study includes research on vitamin D receptor gene polymorphisms, and of chemokine and chemokine receptor gene SNPs, and their role as modifiers of patients’ survival. Dr. Orlow also contributes as an active member of The International Lung Cancer Consortium (ILCCO), an international group of lung cancer researchers established with the aim of sharing comparable data from ongoing lung cancer case-control and cohort studies.

As an ongoing project, Dr. Orlow and her team are examining the relationship between genetic characteristics and cognitive function in patients with brain tumors who have been treated with radiation or chemotherapy, in conjunction with Drs. Correa (Neurology Department) and Satagopan (Biostatistics Department).  In addition to genetic testing, the laboratory conducts functional assays to determine levels of DNA damage, sensitivity to carcinogens, and capacity to repair induced damage in single cells. With these assays, her team has been able to distinguish patients who developed multiple primary lung cancer from those with single primaries. Currently, in a study led by Dr. Ahles (Psychiatry and Behavioral Sciences Department) her laboratory is assessing the levels of DNA damage in the context of changes in neurocognitive function in patients with breast cancer. In addition, Dr. Orlow directs the National Colonoscopy Study (NCS) Repository, and the lab serves as biorepository for other large epidemiologic studies including GEM, EDGE, and WECARE, and the Familial Pancreatic Cancer Registry. Future directions will include, among others, the investigation of host biological factors associated with colorectal cancer and adenomas within the NCS.

Publications

Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, De Pinho RA. “The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53”. Cell 1998;92:713-23. [PubMed Abstract]

Orlow I, Drobnjak M, Zhang Z-F, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C. “Alterations of the INK4A and INK4B Genes in Adult Soft Tissue Sarcomas: Effect on Survival”. J Natl Cancer Inst 1999;91:73-79. [PubMed Abstract]

Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck T, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H and Begg CB. The Prevalence of CDKN2A Germline Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study. Cancer Epidemiol Biomarkers Prev.; 15:1520-5, 2006. [PubMed Abstract]

Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, Downey R, Flores R, Bains M, Rizk N, Dominguez G, Jani J, Berwick M, Begg CB, Kris MG, Rusch VW. DNA damage and repair capacity in lung cancer patients: Prediction of multiple primary tumors. J Clin Oncol 26:3560-3566, 2008.[PubMed Abstract]

Orlow I, Tommasi D, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth A, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol. 2009 129:1972-1982.[PubMed Abstract]

Read more

  1. White KL,  Vierkant RA, Fogarty Z, Charbonneau B, Block MS, Pharoah PD,…, Orlow I,… et al. Analysis of Over 10,000 Cases Finds No Association between Previously-Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiol Biomarkers Prev. 2013 Mar 19. [Epub ahead of print] [PubMed Abstract]

  2. Raimondi S, Gandini S, Fargnoli MC, Bagnardi V, Maisonneuve P, Specchia C, Kumar R, Nagore E, Han J, Hansson J, Kanetsky PA, Ghiorzo P, Gruis NA, Dwyer T, Blizzard L, Fernandez-de-Misa R, Branicki W, Debniak D, Morling N, Landi MT, Palmieri G, Ribas G, Stratigos A, Cornelius L, Motokawa T, Anno S, Helsing P, Wong TH, Autier P, García-Borrón JC, Little J, Newton-Bishop J, Sera F, Liu F, Kayser M, Nijsten T, and the GEM Study Group. Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. BMC Medical Research Methodology 2012; 12:116. [PubMed Abstract]

  3. Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB; GEM Study Investigators. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst, 2012; 104(12):953-6. [PubMed Abstract]

  4. Engel LS, Orlow I, Sima CS, Satagopan J, Mujumdar U, Roy P, Yoo S, Sandler DP, Alavanja MC. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21(10):1856-67. [PubMed Abstract]

  5. Lu Y, Chen X, Beesley J, Johnatty SE, Defazio A; Australian Ovarian Cancer Study (AOCS) Study Group, Lambrechts S, Lambrechts D, Despierre E, Vergotes I,Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Dörk T, Dürst M, Antonenkova N,Bogdanova N, Goodman MT, Lurie G, Wilkens LR, Carney ME, Butzow R, Nevanlinna H, Heikkinen T, Leminen A, Kiemeney LA, Massuger LF, van Altena AM, Aben KK, Kjaer SK, Høgdall E, Jensen A, Brooks-Wilson A, Le N, Cook L, Earp M, Kelemen L, Easton D, Pharoah P, Song H, Tyrer J, Ramus S, Menon U, Gentry-Maharaj A, Gayther SA,Bandera EV, Olson SH, Orlow I, Rodriguez-Rodriguez L, Macgregor S,Chenevix-Trench G. Genome-wide association study for ovarian cancer susceptibility using pooled DNA. Twin Res Hum Genet; 15(5):615-23, 2012.

  6. Hay J, Baguer C, Li Y, Orlow I, Berwick M. Interpretation of melanoma risk feedback in first-degree relatives of melanoma patients. J Cancer Epidemiol, 2012: 374842. [PubMed Abstract]

  7. Willis J, Olson S, Orlow I, Mukherjee S, McWilliams R, Kurtz RC, Klein R. A replication study and genome-wide scan of single nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res, 18(14):3942-51, 2012.

  8. Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben KK, Andrew AS, Bencko V, Bickeböller H, Boffetta P, Brennan P, Brenner H, Duell EJ, Fabianova E, Field JK, Foretova L, Friis S, Harris CC, Holcatova I, Hong YC, Isla D, Janout V, Kiemeney LA, Kiyohara C, Lan Q, Lazarus P, Lissowska J, Le Marchand L, Mates D, Matsuo K, Mayordomo JI, McLaughlin JR, Morgenstern H, Müeller H, Orlow I, Park BJ, Pinchev M, Raji OY, Rennert HS, Rudnai P, Seow A, Stucker I, Szeszenia-Dabrowska N, Dawn Teare M, Tjønnelan A, Ugolini D, van der Heijden HF, Wichmann E, Wiencke JK, Woll PJ, Yang P, Zaridze D, Zhang ZF, Etzel CJ, Hung RJ. Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium.Eur J Cancer, 48(13): 1957-68, 2012. [PubMed Abstract]

  9. Brenner DR, Boffetta P, Duell EJ, Bickeböller H, Rosenberger A, McCormack V, Muscat JE, Yang P, Wichmann HE, Brueske-Hohlfeld I, Schwartz AG , Cote ML, Tjønneland A, Friis S, LeMarchand L, Zhang ZF, Morgenstern H, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Foretova L, Janout V, Bencko V, Schejbalova M, Brennan P, Mates IN, Lazarus P, Field JK, Raji O, McLaughlin JR, Liu G, Wiencke J, Neri M , Ugolini D, Andrew AS, Lan Q , Orlow I, Park BJ, Hung RJ. Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis from the International Lung Cancer Consortium. American Journal of Epidemiology (accepted for publication on Febr 23rd, 2012).

  10. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, and Orlow I. The effect of two functional SNPs in the MDM2 and TP53 genes on the age of onset of cutaneous melanoma. Journal of Investigative Dermatology (accepted Dec 2011) , advance online publication 16 February 2012; doi: 10.1038/jid.2012.15

  11. Rosenberger A, Bickeböller H, McCormack V, Brenner DR, Duell EJ, Tjønneland A, Friis S, Muscat JE, Yang P, Wichmann H-E, Heinrich J, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Janout V, Bencko V, Brennan P, Mates D, Schwartz AG, Cote ML, Zhang Z-F, Morgenstern H, Oh S, Field J-K, Raji O, McLaughlin JR, Wiencke J, LeMarchand L, Neri M, Bonassi S, Andrew A, Lan Q, Hu W, Orlow I, Park BJ, Boffetta P, Hung RJ. Asthma and Lung Cancer Risk: An Analysis from the International Lung Cancer Consortium (ILCCO). Carcinogenesis, 2012. [In press]

  12. Murali R, Goumas C, Fromm L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA,  Kricker A, Orlow I, Rosso S, Thomas NE, Berwick M, Scolyer RA, Armstrong BK for the GEM Study Group. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol, 19(3):1024-1033, 2012.

  13. [PubMed Abstract]

    Orlow I, Roy P, Reiner AS, Yoo, S, Patel H, Paine S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Thomas NE, Gruber SB, Anton-Culver H, Rosso S, Gallagher RP, Dwyer T, Kanetsky PA, Busam K, From L, Begg CB, Berwick M. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer, 130(2):405-418, 2012.

  14. McCormack V, Hung RJ, Brenner DR, Bickeböller H, Rosenberger A, Muscat JE, Lazarus P, Tjønneland A, Friis S, Christiani DC, Chun E-M, LeMarchand L, Rennert G, Rennert HS, Andrew AS, Orlow I, Park B, Boffetta P, Eric J Duell EJ. Aspirin and NSAID use in lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control, (12):1709-20, 2011.

  15. Beesley J, Pickett H A, Johnatty SE, Dunning AM, Chen X, Li J, Michailidou K, Lu J, Rider DN, Palmieri RT, Stutz MD, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Chang-Claude J, Nickels S, Vrieling A, Flesch-Janys D, Wang-Gohrke S, Eilber U, Bogdanova N, Antonenkova N, Runnebaum IB, Dörk T, Goodman MT, Lurie G, Wilkens LR, Matsuno RK, Kiemeney LA, Aben KKH, Marees T, Massuger LFAG, Fridley BL, Vierkant RA, Bandera EV, Olson SH, Orlow I, Rodriguez-Rodriguez L, Cook LS, Le ND, Brooks-Wilson A, Kelemen LE, Campbell I, Gayther SA, Ramus SJ, Gentry-Maharaj A, Menon U, Ahmed S, Baynes C, Pharoah PD, Muir K, Lophatananon A, Chaiwerawattana A, Wiangnon S, Macgregor S, Easton DF, Reddel RR, Goode EL, Chenevix-Trench G. Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One, 6(9):e24987, 2011. [PubMed Abstract]

  16. Berwick M, Begg CB, Armstrong BK, Reiner AS, Thomas NE, Cook LS, Orlow I, Kricker A, Marrett LD, Gruber SB, Anton-Culver H, Millikan RC, Gallagher RP, Dwyer T, Rosso S, Kanetsky P, Lee-Taylor J, for the GEM Study Group. Interaction of CDKN2A and Sun Exposure in the Etiology of Melanoma in the General Population. J Invest Dermatol, 131(12):2500-3, 2011.

  17. Mukherjee S, Simon J, Bayuga S, Ludwig E, Orlow I, Viale A, Offit K, Kurtz RC,Olson SH, Klein RJ. Shared controls to improve the power of genome wide association studies. Hum Hered, 72(1):21-34, 2011.

  18. Mandelcorn-Monson R, Marrett L, Kricker L, Armstrong B, Orlow I, Goumas C,  Paine S , Stefano Rossof, Thomas N,  Millikan RC, Pole JD, Cotignola J, Rosen C, Kanetsky P, Lee-Taylor J, Begg C, Berwick M. Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiol, 35(6):e105-10, 2011.

  19. Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP, Weiss NS, Webb PM, Thompson PJ, Terada K,  Setiawan VW, Rebbeck TR, Prescott J, Orlow I, O’Mara T,  Olson SH, Narod SA, Matsuno RK, Lissowska J, Liang X, Levine DA, LeMarchand L, Kolonel LN, Henderson BR, Garcia-Closas M, Doherty JA, De Vivo I, Chen C, Brinton LA, Akbari MR, Australian National Endometrial Cancer Study Group,  Australian National Endometrial Cancer Study Group, Goodman MT. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One,Feb 8;6(2):e16756, 2011. [PubMed Abstract]

  20. Thomas NE, Kricker A, From L, Busam K, Millikan RC, Ritchey ME, Armstrong BK, Lee-Taylor J, Marrett LD, Anton-Culver H, Zanetti R, Rosso S, Gallagher RP, Dwyer T, Goumas C, Kanetsky PA, Begg CB, Orlow I, Wilcox H, Paine S, Berwick M; Genes, Environment, and Melanoma Study Group. Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis. Cancer Epidemiol Biomarkers Prev, 19(11):2932-2941, 2010. [PubMed Abstract]

  21. Ostrovnaya I, Olshen AB, Seshan VE, Orlow I, Albertson DG, Begg CB. A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med, 29(15):1608-1621, 2010.

  22. Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Ladanyi M, Viale A, Kris MG, Riely G, Miller V, Klein RJ, Matsuo K, and Pao W. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical Cancer Research Clin Cancer Res, 16:755-763, 2010. [PubMed Abstract]

  23. Girard N, Ostrovnaya I,  Lau C, Park B, Ladanyi M, Finley D,  Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clinical Cancer Research, 15:5184-5190, 2009. [PubMed Abstract]

  24. [PubMed Abstract]

    Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol, 129(8):1972-1982, 2009.

  25. Steinberg ML, Hubbard K, Utti C, Clas B, Hwang BJ, Hill HZ., Orlow I. Patterns of persistent DNA damage associated with sun exposure and the glutathione S-transferase M1 genotype in melanoma patients.  Photochemistry and Photobiology, 85:379-386, 2009. [PubMed Abstract]

  26. Olson SH, Orlow I, Bayuga S, Sima C, Bandera EV, Pulick K, Faulkner S, Tommasi D, Egan D, Roy P, Wicox H, Asia A, Modico I, Asad H, Soslow R, Zauber AG.  Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control, 19:955-963, 2008. [PubMed Abstract]

  27. Hubbard K, Steinberg ML, Hill H, Orlow I. Mitochondrial DNA deletions in skin from melanoma patients. Ethn Dis, 18:S2-38-43, 2008.

  28. Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, Downey R, Flores R, Bains M, Rizk N, Dominguez G, Jani J, Berwick M, Begg CB, Kris MG, Rusch VW. DNA damage and repair capacity in lung cancer patients: Prediction of multiple primary tumors. J Clin Oncol, 26:3560-3566, 2008.

  29. Capanu M, Orlow I, Berwick M, Hummer A, Thomas D, Begg CB. The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma. Stat Med, 27:1973-92, 2008. [PubMed Abstract]

  30. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth A, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended dose temozolomide in patients with melanoma. J Clin Oncol, 26:2299-2304, 2008.

  31. Olson S, Orlow I, Simon J, Tommasi D, Roy P, Bayuga S, Ludwig E, Zauber AG, Kurtz RC. Allergies, variants in IL4 and IL4Ra genes, and risk of pancreatic cancer. Cancer Detect Prev, 31:345-351, 2007.

  32. Cotignola, J, Roy P, Patel A, Ishill N, Shah S, Houghton A, Coit D, Halpern A, Busam K, Berwick M, Orlow I. Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression. J Negat Results Biomed,  24;6(1):9, 2007. [PubMed Abstract]

  33. Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M, Orlow I. Matrix metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Medical Genetics, 8:10, 2007. [PubMed Abstract]

  34. Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Wilcox H, Busam K, From L, Berwick M for The GEM Study Group. CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol, 127:1234-43, 2007.

  35. Olson S, Bandera E, Orlow I. Genetic variants, sex steroid hormone levels, and endometrial cancer: A HuGE review. Am J Epidemiol, 165:235-45, 2007.

  36. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck T, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H and Begg CB. The prevalence of CDKN2A germline mutations and relative risk for cutaneous malignant melanoma: An international population-based study. Cancer Epidemiol Biomarkers Prev, 15:1520-5, 2006.

  37. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst, 97:1507-15, 2005.

  38. Orlow I, Berwick M, Hummer A, Begg CB. Absence of association of CDKN2A Ala148Thr with breast cancer. J Med Genet, e-letter July 4th 2005.

  39. Berwick M, Matullo G, Song YS, Guarrera S, Dominguez G, Orlow I, Walker M, Vineis P. Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma. J Clin Oncol, 22:3997-4001, 2004.

  40. Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady MS, Roy P, Song Y, Canchola R, Halpern A, Bolognia J, Eng S, Elahi A, Begg CB. Estimating the relative risk of developing melanoma in INK4A carriers. Eur J Cancer Prev, 131:65-70, 2004.

  41. Berwick M, Song Y, Jordan R, Brady MS, Orlow I. Mutagen sensitivity as an indicator of soft tissue sarcoma risk. Environmental and Molecular Mutagenesis, 38:223-226, 2001.

  42. Orlow I , Roy P, Barz A, Canchola R, Song Y, Berwick M. Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of Human INK4A gene mutations. J. Mol. Diagn, 3:158-163, 2001.

  43. Hernando-Monge E*, Orlow I*, Liberal V, Nohales G, Benezra R, Cordon-Cardo, C. Molecular and functional analyses of the mitotic checkpoint components HSMAD2, HBUB1 and HBUB2 in human cancer”. Int. J. Cancer, 95:223-227, 2001. *both authors contributed equally to the work.

  44. Bisogna M, Calvano JE, Ho G H, Orlow I, Cordon-Cardo C, Borgen P I, Van Zee K J. Molecular analysis of the INK4A and INK4B gene loci in breast carcinoma. Cancer Genetics and Cytogenetics, 125:131-138, 2001.

  45. Orjuela M, Orlow I, Dudas M, Ridaura C, Leal L, Salazar A, Abramson D, Gerald W, Cordon-Cardo C.  Alterations of cell cycle regulators in non-familial retinoblastoma. Human Pathology, 32:537-544, 2001.

  46. Orjuela M, Ponce Castaneda V, Ridaura C, Lecona E, Leal C, Abramson D H, Orlow I, Gerald W, Cordon-Cardo C. Presence of human papilloma virus in tumor tissue from children with retinoblastoma: An alternative mechanism for tumor development. Clinical Cancer Res, 6:4010-4016, 2000.

  47. Szijan I, Orlow I, Dalamon V, Vergani P, Danilowicz K, Mezzadri N, Cordon-Cardo C, Bruno O D.  Alterations in the retinoblastoma pathway of cell cycle control in parathyroid tumors. Oncol Rep,7:421-425, 2000.

  48. Kourea H, Orlow I, Woodruff J, Cordon-Cardo C. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathology, 155:1855-1860, 1999.

  49. Orlow I, Rabbani F, Chin L, Pomerantz J, Ligeois N, Dudas M, DePinho R, Cordon-Cardo C. Involvement of the Ink4a gene  p16 and p19arf in murine tumorigenesis. Int J Oncology 15:17-24, 1999.

  50. Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Meyer F, Rabbani F, Fradet Y, Cordon-Cardo C.  Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol, 155:105-113, 1999.

  51. Rabbani F, Richon V, Orlow I, Lu M-L, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Zhang Z-F, and Cordon-Cardo C.  Prognostic significance of E2F-1 in bladder cancer: Genotypic and phenotypic characterization. J Natl Cancer Inst, 91:874-881, 1999.

  52. Orlow I, Drobnjak M, Zhang Z-F, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C. Alterations of the INK4A and INK4B genes in adult soft tissue sarcomas: Effect on survival”. J Natl Cancer Inst, 91:73-79, 1999.

  53. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, De Pinho RA.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53.  Cell, 92:713-23, 1998.

  54. Orlow I, Lacombe L, Pellicer I, Rabbani F, Delgado R, Zhang ZF, Szijan I, Cordon-Cardo C.  Genotypic and phenotypic characterization of the histoblood group ABOH in primary bladder tumors. Int J Cancer, 75: 819-24, 1998.

  55. Bonilla F, Orlow I, Cordón-Cardó C. Mutational study of the p16INK4A and p57KIP2 genes in hepatocellular carcinoma. Int J Oncol, 12:583-588, 1998.

  56. Zhang Z-F, Shu X-M, Cordón-Cardó C, Orlow I, Lu M-L, Millon TV, Cao P-Q, Connolly-Jenks C, Dalbagni G, Lianes P, Lacombe L, Reuter VE, Scher H.  Cigarette smoking and chromosome 9 alterations in bladder cancer. Cancer Epidem Biomarkers Prev, 6:321-326, 1997.

  57. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang Z-F, Cordon-Cardo C. Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer, 69:110-113, 1996.

  58. Lacombe L, Orlow I, Silver D, Cordon-Cardo C.  Analysis of p21WAF1/CIP1 in primary bladder tumors. Oncology Res, 8:409-414, 1996.

  59. Orlow I, Iavarone A, Miller S, Bonilla F, Latres E, Lee M-H, Massague J, Weissman BE, and Cordon-Cardo C.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms tumors. Cancer Res, 56:1219-1221, 1996.

  60. Santos Buch C, Hall Jr H, Farfan F, Orlow I, Firpo A, von Kreuter B, Becker CG. Characterization of the tobacco glycoprotein surface binding property of heart and skeletal muscle cells. Arch Toxicol, 69: 149-159, 1995.

  61. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang Z-F, Beach D, Cordon-Cardo C.  Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst, 87:1524-1529, 1995.

  62. Orlow I, Lianes P, Lacombe L, Reuter VE, Cordon-Cardo C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res, 54: 2848-2851, 1994.

  63. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, Skolnick M, Cordon-Cardo C, Kamb A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol, 146:1199-1206, 1994.

  64. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst, 86:1325-1330, 1994.

  65. Mathias S, Younes A, Kan C-C, Orlow I, Joseph C, Kolesnick RN. Activation of the sphingomyelin pathway in intact EL4 cells and in cell-free system by IL-1b”. Science, 259:519-522, 1993.

  66. Michaeli J, Busquets X, Orlow I, Younes A, Colomer D, Marks PA, Rifkind RA, Kolesnick RN.  A rise and fall in 1,2- diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis. J Biol Chem, 267: 23463-23466, 1992.

My Projects

Related topics:

Learn more
The International Lung Cancer Consortium (ILCCO)